OncoMatch/Clinical Trials/NCT04249154
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer
Is NCT04249154 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Eligard for prostate cancer.
Treatment: Eligard — Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the surgical procedure. The failure rate is even more pronounced in those patients that present with high prostate specific antigen (PSA) levels, pT3 disease, positive margins and Gleason score ≥8 with an estimated 75% failure rate at 10 years. Post-operative radiotherapy (RT) has been shown in three randomized trials to significantly decrease the biochemical failure rate and in one of the trials a survival benefit was also seen with the addition of post-operative RT and is considered by many investigators standard therapy in patients with pathological high-risks factors even in absence of biochemical failure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ZUBROD 0–1
Prior therapy
Must have received: radical prostatectomy — primary treatment
after a radical prostatectomy as primary treatment
Cannot have received: androgen deprivation
Previous exposure to androgen deprivation
Cannot have received: chemotherapy
Chemotherapy before or after prostatectomy
Cannot have received: pelvic radiotherapy
Prior pelvic radiotherapy
Lab requirements
Blood counts
hemoglobin ≥ 10 g/dl (patients may be transfused in order to achieve this level); platelets ≥ 100 000 cells/mm3 and a white blood cell count of ≥ 4000 cells/ml3
Liver function
ast or alt <2 x the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify